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PTEN is the most important negative regulator of the PI3K signaling pathway. In addi-
tion to its canonical, PI3K inhibition-dependent functions, PTEN can also function as a
tumor suppressor in a PI3K-independent manner. Indeed, the PTEN network regulates a
broad spectrum of biological functions, modulating the flow of information from membrane-
bound growth factor receptors to nuclear transcription factors, occurring in concert with
other tumor suppressors and oncogenic signaling pathways. PTEN acts through its lipid
and protein phosphatase activity and other non-enzymatic mechanisms. Studies conducted
over the past 10 years have expanded our understanding of the biological role of PTEN,
showing that in addition to its ability to regulate proliferation and cell survival, it also plays
an intriguing role in regulating genomic stability, cell migration, stem cell self-renewal, and
tumor microenvironment. Changes in PTEN protein levels, location, and enzymatic activ-
ity through various molecular mechanisms can generate a continuum of functional PTEN
levels in inherited syndromes, sporadic cancers, and other diseases. PTEN activity can
indeed, be modulated by mutations, epigenetic silencing, transcriptional repression, aber-
rant protein localization, and post-translational modifications. This review will discuss our
current understanding of the biological role of PTEN, how PTEN expression and activity
are regulated, and the consequences of PTEN dysregulation in human malignant tumors.
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WHAT IS PTEN?
PTEN stands for Phosphatase and TENsin homolog deleted on
chromosome 10 and is a classical tumor suppressor gene located in
the 10q23 region of chromosome 10 encoding for a 403-aminoacid
multifunctional protein (predicted MW 47 kDa), which possesses
lipid and protein phosphatase activities. PTEN was identified in
1977 by three independent groups: two groups used a positional-
cloning approach, whereas the third group identified PTEN by a
biochemical approach, which aimed to identify a gene encoding for
a phosphatase with tensin and auxilin homology (1–3). The crystal
structure of PTEN was resolved by Lee et al. in 1999, although two
flexible regions of unknown function had to be deleted for techni-
cal reasons; crystal structure revealed the presence of a phosphatase
domain, a C2 lipid membrane-binding domain, and a class I PDZ
binding motif at the C-terminus, which recognizes target proteins
(4). The PTEN gene is almost ubiquitously expressed in mammals
throughout early embryogenesis (5); although the main protein
subcellular localization is cytoplasmic and/or membrane bound,
nuclear localization has been described and bears important func-
tional consequences (6). In addition, it has been reported that the
recently identified PTEN protein variants, such as PTEN-Long,
can exit, exist, and function outside the cell in a paracrine type
fashion (7).
PTEN acts as a classical tumor suppressor, mainly involved
in the homeostatic maintenance of the phosphatidylinositol 3
kinase (PI3K)/AKT cascade (Figure 1A). PI3K, a lipid kinase acti-
vated by receptor tyrosine kinases, G protein-coupled receptors,
and RAS activation, converts the lipid second messenger phos-
phatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol
3,4,5-trisphosphate (PIP3); PIP3 recruits phosphatidylinositol-
dependent kinase 1 (PDK1) and AKT to the plasma membrane,
where AKT is phosphorylated on Thr308 by PDK1 and on Ser473
by the mammalian target of rapamycin (mTOR) complex 2
(mTORC2) (8, 9). By dephosphorylating PIP3 to PIP2, PTEN
reverses the action of PI3K, thereby hampering all downstream
functions controlled by the AKT/mTOR axis, such as cycle pro-
gression, induction of cell death, transcription, translation, stim-
ulation of angiogenesis, and stem cell self-renewal (10–17). Even
though the biological effects of PTEN are dominated by its ability
to dephosphorylate lipid substrates, PTEN has also been reported
to exhibit protein phosphatase activity, responsible for some of its
biological effects, including inhibition of cell migration and cell-
cycle arrest (18, 19). More recently, a growing list of functionally
relevant, phosphatase-independent activities have been described
(Table 1) (20, 21).
PTEN function is commonly lost in a large proportion of
human cancers through somatic mutations, gene silencing, or
epigenetic mechanisms (Table 2). Tumor-associated mutations
may occur in all PTEN domains, thus implying that each distinct
protein region (and each related PTEN activity) may be patho-
logically relevant to cancer initiation and progression. In addi-
tion, emerging evidence shows that PTEN gene/protein dosage is
quantitatively relevant during tumor development, as partial loss
of PTEN function (haploinsufficiency) is sufficient to promote
growth in some human malignancies. The mechanisms involved
in regulation of PTEN dosage include methylation, micro-RNA
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FIGURE 1 | Cytoplasmic and nuclear PTEN functions. PTEN acts in
regulating a wide spectrum of biological functions, at least in part determined
by its subcellular localization. (A) In the cytoplasm PTEN dephosphorylates
PIP3 to PIP2, thereby reversing the action of PI3K and hampering all
downstream functions controlled by the AKT/mTOR axis, such as cycle
progression, induction of cell death, transcription, translation, stimulation of
angiogenesis, and stem cell self-renewal. In addition, through its protein
phosphatase activity directed against FAK and SHC, PTEN modulates complex
pathways affecting cell migration. (B) In the nucleus, PTEN cooperates in
maintaining genomic integrity, repairing DNA double-strand breaks,
controlling homologous recombination, and promoting ubiquitin-dependent
degradation of oncoproteins such as PLK1 and AURK. In addition, PTEN
controls cell-cycle progression by modulating ERK phosphorylation and cyclin
D1 levels and regulates chromatin remodeling by binding to histone H1.
(miR) or pseudogene expression, and protein phosphorylation
(31–33). In this review, we will discuss the cellular functions
controlled by PTEN, the molecular mechanisms of the subtle
regulation of PTEN expression and function, and the role of its
mutational/expression status in cancer.
CELLULAR FUNCTIONS CONTROLLED BY PTEN
PTEN-MEDIATED REGULATION OF METABOLIC PATHWAYS
The PTEN/PI3K pathway may influence key steps in metabolic
pathways during cell proliferation and tumorigenesis. Recent
data from two independently generated transgenic mouse mod-
els, based on two similar PTEN-containing bacterial artificial
chromosomes (BAC), have shown that PTEN is involved in the
control of metabolic pathways through PI3K-dependent and -
independent functions (30, 84). Garcia-Cao et al. demonstrated
that transgenic mice overexpressing PTEN show reduced body
size, due to decreased cell number, increased energy expendi-
ture, and reduced body fat accumulation. Cells derived from these
mice show reduced glucose and glutamine uptake, increased mito-
chondrial oxidative phosphorylation, and resistance to oncogenic
transformation. Ortega Molina et al. showed that mice carry-
ing additional genomic copies of PTEN have increased energy
expenditure and are protected from metabolic pathologies and
cancer. Moreover, a recent human study demonstrates that PTEN
haploinsufficiency is a monogenic cause of profound constitutive
insulin sensitization that is apparently obesogenic. In particular,
the authors demonstrated that patients who are heterozygous car-
riers of PTEN mutations, which cause Cowden syndrome, are at
increased risk of obesity and cancer, but at decreased risk of dia-
betes due to enhanced insulin sensitivity (85). The role of PTEN in
insulin-stimulated glucose uptake is controversial in the literature.
Substantial evidence suggests a role for PTEN in the regulation
of glucose uptake, due to its ability to modulate insulin signal-
ing (86, 87). For example, Nakashima et al. have shown that
PTEN overexpression in adipocytes inhibits insulin-stimulated,
PI3K activation-dependent 2-deoxyglucose uptake, and glucose
transporter type 4 (GLUT4) translocation, a key event in insulin
signaling (88), which ultimately leads to decreased glucose cellu-
lar uptake. Conversely, Mosser et al. suggest that PTEN does not
modulate GLUT4 translocation and metabolic functions of insulin
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Table 1 | Selected cell functions controlled by specific PTEN activities/domains and their dependency on regulation of the PI3K pathway.
Functions controlled by PTEN PTEN activity involved PTEN domain involved PI3K/AKT
dependency
References
Cell proliferation Lipid phosphatase Phosph/C2 (PBD?) Yes (4, 17)
Cell survival Lipid phosphatase Phosph/C2 (PBD?) Yes (4, 17)
Cell metabolism Lipid phosphatase Phosph/C2 (PBD?) Yes (4, 17)
Cell motility Lipid and protein phosphatase Phosph/C2 Partiala (4, 17)
Angiogenesis Lipid phosphatase Phosph/C2 (PBD?) Yes (4, 17)
Chromosomal stability Nuclear localization (phosphatase independent) C-Tail (4, 6, 17, 22)
Double-strand DNA breaks repair Nuclear localization (phosphatase independent) C-Tail No (4, 6, 17, 22, 23)
Cell-cycle progression Lipid phosphatase Phosph/C2 (PBD?) Yes (4, 17)
APC/C-CDH1-dependent PLK
and AURK degradation
Nuclear localization (phosphatase independent) Not determined No (6, 24)
Chromatin remodeling Direct interaction with H1 C-Tail No (25)
JNK pathway activation Not determined Not determined No (26)
eIF2α- or MSP58-mediated
transformation
Not determined (phosphatase independent) C-Tail No (4, 17, 27, 28)
SRC activation Protein phosphatase Phosphatase No (17, 29)
Paracrine suppression of AKT
activation
Secretion and lipid phosphatase (PTEN-Long)b/Phosph/C2 (PBD?) Yes (7)
Mitochondrial metabolism and
ATP production
Phosphatase PTENαc/Phosph No (17, 30)
aPTEN effects on cell motility are related to the PI3K-dependent formation/degradation of localized intracellular PIP3 gradients, as well as to the PI3K-independent
dephosphorylation of FAK, SHC, and SRC family members.
bPTEN-Long is a translational variant of PTEN endowed with lipid phosphatase activity and the additional 173 aminoacids at the N-terminus constitute a secretion
sequence that allows the protein to exit, exist, and function outside the cell.
cPTENα is a N-terminally extended form of PTEN that localizes to the mitochondria and regulates mitochondrial metabolism through the induction of cytochrome c
oxidase activity and ATP production.
under normal physiological conditions (89). However, Morani
et al. using genetic manipulations of PTEN expression, have shown
the involvement of PTEN in the regulation of membrane expres-
sion of glucose transporter type 1 (GLUT1), suggesting that PTEN
regulates glucose uptake, at least in transformed cells, such as thy-
roid cancer cells (90). On the other hand, PTEN is involved in
the modulation of gluconeogenesis through inhibition of fork-
head box O (FOXO) 1, peroxisome proliferator activated receptor
(PPAR)γ, and PPARγ-coactivator 1a (84).
PTEN ROLE IN CELL MOTILITY
Among its many functions, PTEN plays an important role in the
regulation of cell motility, particularly, in controlling the direc-
tionality of chemotaxis. Studies conducted in Dictyostelium over
the past years suggest that both PI3K and PTEN activities, and
the resulting formation of localized intracellular PIP3 gradients,
are required during chemotaxis (91–93). In these studies, the
authors show that during chemotaxis PIP3 levels are enriched
at the leading edge of migrating cells, while PTEN relocalizes
at the opposite side of the cell; as a result, when PTEN is lost,
Dictyostelium cells have defects in polarization and chemotaxis
(94, 95). Several in vitro studies have shown that PTEN phos-
phatase activity is required to regulate cellular migration with
some reports indicating the involvement of the C2 domain and
another implicating PTEN’s protein phosphatase activity (96–
99). In particular, it has been shown that PTEN overexpression
is able to inhibit the spreading of glioblastoma cells and the
migration and spreading of fibroblasts. On the other hand, knock-
down of endogenous PTEN expression enhanced cell migration
in fibroblasts possibly through the involvement of focal adhesion
kinase (FAK) (100): PTEN dephosphorylates FAK, a cytoplas-
mic phosphoprotein activated by integrins, thereby inhibiting cell
migration. PTEN may also dephosphorylate SHC, thus inhibiting
downstream pathways, including the mitogen activated protein
kinase (MAPK) pathway, which leads to the modulation of cell
motility (Figure 1A). Recent studies, aimed at understanding the
role of PTEN in cell motility, suggest that both lipid and protein
phosphatase activities contribute to PTEN-mediated regulation
of migration, through interactions with Rac1 and the SRC family
kinase, FYN (101).
PTEN AND ANGIOGENESIS
Recent studies performed in glioblastoma cell lines suggest that
PTEN is potentially important in the control of angiogenesis
within brain tumors. In fact, reconstitution of PTEN expression in
the PTEN−/−U87 MG glioma model caused a dramatic decrease
in tumor growth in vivo and increase in mice survival, without
significantly effecting the proliferation of these cells in vitro. The
observed effect was due to the induction of thrombospondin-
1, a negative regulator of angiogenesis, consequently reducing
recruitment of blood vessels to the tumor (102). In addition,
PTEN loss can also facilitate glioma growth by promoting HIF1
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Table 2 | Incidence and prognostic significance of PTEN alterations in PHTS and sporadic human cancers.
Malignancy type Increased risk
in PHTS
Molecular mechanism(s) of
PTEN alteration
Prognostic/therapeutic implications
of PTEN loss
References
Breast cancer Yes (85 vs. 12% LR) Mutations <5%, LOH 40%, methylation
50%, and loss of expression ~40%
Resistance to endocrine and
HER2-targeted therapy
(34–39)
Thyroid cancer Yes (35 vs. 1% LR) Homozygous deletion <10%, methylation
>50%, rearrangement in most papillary
thyroid carcinomas
PTEN loss cooperates with other
genetic alterations and is more frequent
in aggressive cancers (ATC)
(34, 35, 40)
Kidney cancer Yes (34 vs. 1.6% LR) Homozygous deletion or somatic
mutations 1–5% of ccRCC and 6.4%
of chRCC
High PTEN expression correlates with
better DSS and better response to
VEGFR-TKI
(34, 35,
41–43)
Endometrial cancer Yes (28 vs. 2.6% LR) Mutations 15–88% depending on specific
subtype, methylation 18%, and loss of
expression 20%
Favorable or unfavorable prognostic
implications depending on mutation type
and association with obesity and/or other
factors
(34, 35,
44, 45)
Colorectal cancer Yes (9 vs. 5% LR) Up to 18% mutated and up to 19% LOH
depending on tumor type, concomitant
promoter hypermethylation
Inconsistent negative prognostic impact;
lack of response to EGFR-targeted mAbs
(34, 35,
46–49)
Melanoma Yes (6 vs. 2% LR) LOH 30–60%, mutation 10–20%
(metastases), and >50% frequent
promoter methylation in patients with XP
Inconsistent association with prognosis;
subcellular localization important;
decreased response to BRAF-selective
inhibitors
(34, 35,
50–53)
Glioma Dysplastic gangliocytoma
of the cerebellum in LD
LOH >70%, mutation 44% (coincident
with LOH) and miR-26a amplification
Mutations associated with shorter OS (34, 35,
54, 55)
Prostate cancer NR Homozygous deletion and mutation in up
to 20%, miR-22 and miR-106b-25 cluster
overexpression
Early recurrence after surgery,
development of metastases, hormone
refractoriness, and shorter survival
(34, 56–58)
Leukemia/lymphoma NR Deletion 10% of T-ALL and 27% mutation
in T-ALL, aberrant RNA splicing in AML
Shorter survival and resistance to
NOTCH inhibitors in T-ALL
(34, 59–70)
Lung cancer Occasional Mutations 6–9% (predominantly
squamous), promoter methylation 24%,
frequent miR-21 upregulation, and loss of
PTEN 24–44%
Inconsistent association with poor
prognosis, resistance to EGFR-targeted
therapies
(34, 71–75)
Bladder cancer NR LOH 23%, homozygous deletion 6%,
mutation 23% (late stage), and decreased
or absent expression 53%
Significant association with recurrence in
pTa and progression in pT1
(34, 76, 77)
Liver cancer NR Mutation ~5%, deletion or loss of
expression ~50%, and protein expression
downregulated by HBV and HCV viral
proteins
Association with high tumor grade,
advanced stage, high αFP expression;
increased recurrence, shorter OS and
possibly resistance to sorafenib
(34, 78, 79)
Pancreatic cancer NR Hetero or homozygous deletions 15%,
loss of protein expression ~70%
(exocrine); LOH ~50%, altered subcellular
localization (endocrine)
Significantly increased recurrence and
metastases, shorter OS (exocrine);
negative prognostic impact modulated by
PR and mTOR expression (endocrine)
(34, 80–82)
Phaeochromocytoma NR Mutations rare, LOH ~40% More frequent in malignant versus benign
lesions
(34, 83)
PHTS, PTEN hamartoma tumor syndromes; LR, lifetime risk; LOH, loss of heterozygosity; ATC, anaplastic thyroid carcinoma; ccRCC, clear cell renal cell carcinoma;
chRCC, chromophobe renal cell carcinoma; DSS, disease-specific survival; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitors; EGFR,
epidermal growth factor receptor; mAbs, monoclonal antibodies; XP, xeroderma pigmentosum; LD, Lhermitte–Duclos syndrome; miR, misro-RNA; OS, overall survival;
T-ALL,T-cell acute lymphoblastic leukemia; HBV, hepatitis B virus; HCV, hepatitis C virus; αFP, alpha fetoprotein; PR, progesterone receptor; mTOR, mammalian target
of rapamycin.
Frontiers in Oncology | Molecular and Cellular Oncology February 2015 | Volume 5 | Article 24 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Milella et al. Broad spectrum of PTEN biological functions
expression and activity (103). In both cases, PTEN’s ability to
counteract neo-angiogenesis appears to be related to its lipid
phosphatase activity and to suppression of signaling through
the PI3K/AKT/mTOR axis. Our group and others have indeed
demonstrated that the mTOR/eIF4E axis downstream of PI3K,
plays a crucial role in the regulation of vascular endothelial
growth factor (VEGF) production in breast cancer cells through
increased hypoxia inducible factor 1α (HIF1α) expression and
transcriptional activation. This suggests that the anti-tumor activ-
ity observed after PI3K (and especially mTOR) cascade inhibition
may be due, at least in part, to the anti-angiogenic effects observed
with mTORC1 inhibitors, such as temsirolimus (104). Along these
lines, recent studies from our group have shown that the anti-
angiogenic activity observed with MEK inhibitors in melanoma
models in vitro and in vivo (105) is due, at least in part, to MEK
inhibition-induced upregulation of PTEN expression. Indeed, in
cell lines in which PTEN function is offset by the expression
of a dominant negative PTEN mutant (DN-PTEN), the effects
observed on VEGF production after MEK inhibitor treatment are
partially blocked (106).
ROLE OF PTEN IN THE NUCLEUS
PTEN plays an important tumor suppressor role in the nucleus
(Figure 1B) and the absence of nuclear PTEN is associated with
more aggressive cancers (107–109). Recent findings have shown
that the PTEN protein is present in the nucleus of cell lines and
tissue cells, even if the mechanisms of PTEN nuclear localization
have yet to be fully elucidated (109–112). Given the absence of
a classical nuclear localization signal sequence (NLS) or nuclear
export sequences (NES), numerous molecular mechanisms have
been proposed, including simple diffusion, active shuttling by
the RAN GTPase, or phosphorylation-dependent shuttling and
monoubiquitylation-dependent import (6, 113). Trotman et al.
have demonstrated that PTEN nuclear import is mediated by its
ubiquitination by the E3 ligase, neural precursor cell expressed,
developmentally downregulated-4-1 (NEDD4-1) (114). Recently,
sumoylation has also been reported to mediate PTEN nuclear
retention (115). Within the nucleus, PTEN has been shown to
interact with the centromere specific binding protein C (CENP-C)
to modulate centrosome stability (22). Moreover,PTEN is involved
in DNA-damage responses through upregulation of the transcrip-
tion of Rad51, a key component of the homologous recombination
system, which repairs DNA double-strand breaks (22, 23). In addi-
tion, nuclear PTEN controls cell-cycle progression by decreasing
cyclin D1 levels in the nucleus and regulates cellular senescence
through anaphase promoting complex (APC)-CDH1-mediated
protein degradation (6, 24) (Figure 1B). Several reports suggest
that nuclear PTEN functions may be independent of its cat-
alytic activity and may be regulated by PTEN physical interaction
with nuclear target proteins, such as p53, microspherule protein 1
(MSP58; also known as MCRS1) or HIF1α (27, 116, 117). Recent
evidence also demonstrates that PTEN is involved in transcrip-
tional regulation through the control of chromatin remodeling.
Chen et al. have shown that PTEN physically associates with his-
tone H1, through its C-terminal domain, to maintain a condensed
chromatin structure. Loss of PTEN or its C-terminal portion
promotes chromatin decondensation and gene activation (25).
ALTERNATIVE PTEN VARIANTS
Recent studies have led to the identification of new PTEN variants:
PTEN-Long and PTENα. Hopkins et al. identified an alterna-
tive initiation codon, as compared to the canonical start site on
the PTEN promoter, which predicts the expression of a longer
PTEN variant. PTEN-Long contains a 173-amino acid domain
at its N-terminus followed by the classical 403 amino acids of
PTEN. PTEN-Long is a translational variant of PTEN endowed
with lipid phosphatase activity and the additional amino acids
constitute a secretion sequence that allows the protein to exit,
exist, and function outside the cell (7, 118). Recent studies have
reported that PTEN-Long can be detected in human serum and
plasma and can act as a therapeutic factor involved in tumor regres-
sion (7, 119). Hopkins et al. have demonstrated that the purified
PTEN-Long protein injected in mice is taken up by several tis-
sues and antagonizes AKT signaling inducing an increase in blood
glucose levels. In addition, they found PTEN-Long has tumor-
suppressive function inducing tumor cell death in vitro and in vivo
(7). The molecular mechanisms involved in PTEN-Long regula-
tion have yet to be defined, but the long variant can be coexpressed
with the classical PTEN isoform. PTEN-Long is expressed in nor-
mal tissues such as the breast and brain, whereas its expression
levels are lower in human breast tumors and mouse models of
glioblastoma (7, 20, 118).
Recently, Liang et al. have identified another N-terminally
extended form of PTEN (PTENα) that localizes to the cytoplasm
and the mitochondria and is involved in the regulation of mito-
chondrial metabolism through the induction of cytochrome c
oxidase activity and ATP production. Moreover, PTENα promotes
energy production and interacts with canonical PTEN to increase
PTEN-induced putative kinase 1 (PINK1) protein levels (120).
FINE TUNING OF PTEN ACTIVITY
PTEN dysfunction plays a crucial role in the pathogenesis of hered-
itary and sporadic tumors (34, 121). During tumor development,
mutations, and deletions of PTEN lead to the inactivation of
its enzymatic activity, with consequently increased cell prolifer-
ation and reduced cell death. In addition to genomic inactivation,
many other pathogenic mechanisms involved in the repression of
PTEN gene expression or in the aberrant subcellular compart-
mentalization of the protein are associated with tumorigenesis.
Several different mechanisms are known to fine tune PTEN expres-
sion and function, including transcriptional regulation, post-
transcriptional regulation by non-coding RNAs,post-translational
modifications, and protein–protein interactions.
TRANSCRIPTIONAL REGULATION
PTEN transcription is negatively and positively regulated by dif-
ferent transcription factors. p53 can upregulate PTEN, resulting in
a complex interplay between these two tumor suppressors (122).
EGR1 binds to the PTEN promoter and upregulates PTEN expres-
sion in response to insulin-like growth factor-2 (IGF-2) stimula-
tion or radiation (123, 124). PPARγ can also upregulate PTEN
gene expression (125).
On the contrary,SNAIL,c-Jun,and nuclear factor kappa-B (NF-
kB) have been reported to negatively regulate PTEN transcription
(106, 126, 127). Active NOTCH1 has been reported to act as both
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a negative and a positive regulator of PTEN transcription through
interacting with MYC and CBF-1, respectively (128, 129). Our
group and others have shown that c-Jun is involved in the regula-
tion of PTEN expression (106, 130, 131). In particular, our group
has demonstrated that PTEN is a target of a re-wired MEK–ERK–
c-Jun survival pathway, occurring in BRAF-mutant melanoma,
but also in other malignant tumors, as well as in normal fibrob-
lasts. Indeed, upon genetic and/or pharmacologic modulation of
ERK activity, c-Jun and PTEN are counter-regulated with strict
time/dose dependency. Moreover, ERK-independent genetic mod-
ulation of c-Jun expression exerts the same effects on PTEN reg-
ulation and expression of a constitutively active MEK/ERK fusion
protein in non-transformed fibroblasts concomitantly upregulat-
ing c-Jun and downregulating PTEN expression. These data reveal
that ERK-dependent regulation of PTEN expression, occurring at
least in part through c-Jun-mediated transcriptional repression, is
a physiological regulatory mechanism, which takes place in both
normal and cancer cells of different histological origin (106).
POST-TRANSCRIPTIONAL REGULATION
micro-RNA contribute to the regulation of PTEN expression in
many tumors. In fact, it has been demonstrated that the onco-
genic miR-21, one of the most frequently upregulated miRs in
cancer, directly targets and downregulates PTEN in specific can-
cers, including hepatocellular, ovarian, and lung cancer (132, 133).
Recently, it has been shown that miR-25 controls PTEN levels
in human tumors and contributes to experimental tumorigene-
sis (106, 134). As it has been discussed above for the involvement
of c-Jun, miR-25 provides another interesting link between the
MEK/ERK and PI3K/PTEN/AKT/mTOR pathways. Our group has
recently shown that miR-25 expression levels are controlled by
ERK activation status, which in turn regulates PTEN protein levels
in melanoma cells. The MYC oncogene also may downregulate
PTEN through increased expression of miR-19 (135).
In recent years, new findings have lead to hypothesize that both
non-coding and protein-coding genes possess a novel mRNA-
dependent non-coding function that enables them to act as a decoy
to block the effect of specific miR on other RNA in a model termed
the competing endogenous RNA (ceRNA) hypothesis (17, 134).
This appears to be the case for the PTEN pseudogene 1 (PTENP1)
that shares significant sequence identity with PTEN mRNA in
regions that harbor miR target sites. PTENP1 was found to regulate
PTEN expression through sequestration of PTEN-targeting miR,
thereby increasing the half-life of PTEN mRNA and increasing
PTEN protein levels (17, 134).
EPIGENETIC SILENCING
Epigenetic silencing of PTEN expression through aberrant methy-
lation of the gene promoter or of histone modifications has
been observed in many types of cancers (17, 34). Several stud-
ies have shown that silencing of PTEN transcription is often due
to the presence of hypermethylated CpG islands in the PTEN
promoter. Hypermethylation has been observed in colorectal,
endometrial, breast, gastric, prostate, melanoma, and lung cancer
(19, 50, 71, 136, 137). Lu et al. have demonstrated that the zinc-
finger transcription factor sal-like protein 4 (SALL4) represses
PTEN transcription by recruiting an epigenetic repressor complex
(Mi-2/NuRD) (138). Histone deacetylase inhibitors, on the other
hand, are able to increase PTEN transcription in fibroblasts (139).
POST-TRANSLATIONAL MODIFICATIONS
PTEN function is also regulated by post-translational modifi-
cations, including phosphorylation, acetylation, oxidation, and
ubiquitination. PTEN has six phosphorylation sites, which have
been implicated in the modulation of its tumor suppressor
functions, stability, and subcellular compartmentalization (140).
Caseine kinase 2 (CK2) is a protein kinase that phosphorylates
PTEN on Thr366, Ser370, Ser380, Thr382, Thr383, and Ser385.
CK2-mediated phosphorylation stabilizes PTEN, but creates a
closer conformation that decreases interactions with binding part-
ners and reduces its plasma membrane localization (111, 141).
PTEN can be also phosphorylated by LKB1 on Ser385, resulting in
its inactivation (142). Glycogen Synthase Kinase 3β (GSK3β) phos-
phorylates PTEN at Ser362 and Thr366, decreasing its phosphatase
activity (143). PTEN phosphorylation can also be mediated by the
kinases RAK, ROCK, JNK, JNKK, and SRC (141, 143–145).
Another mechanism involved in PTEN regulation is through
the ubiquitin/proteasome pathway. NEDD4-1 is an E3 ubiquitin–
protein ligase involved in promoting PTEN ubiquitin-mediated
degradation (146). Recent evidence has identified WWP2
as an additional E3 ubiquitin ligase, which mediates PTEN
ubiquitination-dependent degradation. Amodio et al. have shown
that in some tumors, such as non-small-cell lung cancer (NSCLC),
PTEN downregulation via ubiquitin-mediated degradation is an
important mechanism leading to loss of PTEN activity (147). Pre-
vious studies have suggested that PTEN functions can be regulated
by acetylation. The acetyltransferase P300/CBP-associated factor
(PCAF) has been demonstrated to acetylate PTEN at Lys125 and
Lys128 sites, which, in turn, negatively regulate PTEN catalytic
activity (148). Catalytic PTEN activity is also controlled by reac-
tive oxygen species (ROS). In particular, recent studies have shown
that ROS regulate PTEN activity by oxidative-stress-induced for-
mation of a disulfide bond between the active site Cys124 and
Cys7 (149).
PROTEIN-PROTEIN INTERACTIONS
Some cellular proteins, including phosphatases, can affect PTEN
functions either directly or indirectly via protein–protein inter-
actions. Such protein–protein interactions may influence PTEN
activity by modifying its conformation, stability, subcellular com-
partmentalization, and lipid membrane binding. For example,
membrane-associated guanylate kinase inverted 2 (MAGI2) bind-
ing to PTEN increases its activity (150). Conversely, DJ1 (also
known as PARK7: Parkinson protein 7) binds PTEN under oxida-
tive conditions, thereby inhibiting its activity. DJ1 expression is
associated with increased AKT activity and poor prognosis in
different tumor types (151, 152). Some proteins that interact
with PTEN are involved in its translocation across the cytoplasm
and subcellular localization (21). Microtubule-associated Ser/Thr
kinase 2 (MAST2) is another PTEN regulator. Terrien et al. have
recently demonstrated that when MAST2 and PTEN form a com-
plex, the phosphorylation of PTEN by MAST2 drastically increases
and destabilization of this interaction promotes neuronal cell sur-
vival, through the alteration of PTEN intracellular trafficking
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(153). Zmajkovicova et al., have demonstrated that interaction
between PTEN, MEK1, and MAGI1 is necessary for PTEN mem-
brane recruitment and PIP3 turnover and AKT signaling (154).
MEK1 and MAGI1 are both essential for complex formation. In
fact, MEK1 binding to MAGI1 promotes both complex formation
and PTEN translocation onto the membrane.
PTEN LOSS IN HUMAN CANCER
Germline mutations of PTEN are the underlying genetic causes of
related disorders clinically referred to as PTEN hamartoma syn-
dromes (PHTS) including: Cowden syndrome, Bannayan–Zonana
syndrome, Lhermitte–Duclos syndrome, Proteus syndrome, and
Proteus-like syndrome. Mutations responsible for these syn-
dromes result in a non-functional or absent protein, which causes
uncontrolled cell growth, leading to tumor (either benign or
malignant) growth (34, 155–157). Cowden syndrome is the best-
described syndrome within PHTS, with approximately 80% of
patients having germline PTEN mutations. Patients with Cowden
syndrome have a high risk for benign and malignant tumors of the
breast (lifetime risk – LR-85%), thyroid (LR 35%), kidney (renal
cell carcinoma – RCC-, LR 33%), and endometrium (LR 28%),
which correspond to sporadic tumor types that commonly exhibit
somatic PTEN inactivation (155, 157, 158) (Table 2). In addition,
increased risk for colorectal cancer (9%) and melanoma (6%), pre-
viously not believed to be part of PHTS, have also been described
(35). In addition to the well-characterized role of PTEN mutations
in PHTS syndromes, new evidence shows that PTEN mutation is
one of the most validated causes of autism spectrum disorders,
intellectual disability, and extreme macrocephaly (159, 160).
The PTEN tumor suppressor is frequently lost, either partially
or fully, from many sporadic tumor types. Somatic inactivation
of PTEN occurs in a wide range of neoplastic diseases, including
melanoma, glioblastoma, colon, and endometrial cancers (161,
162) (Table 2). More than a decade of research has expanded our
knowledge on PTEN’s role in cancer. Experiments performed in
transgenic mice have demonstrated that loss of both copies of
the PTEN gene results in embryonic lethality, whereas PTEN het-
erozygous mutants develop a diverse range of dysplasias in a wide
spectrum of tissues with high incidence of prostate and colon
cancer (163, 164). Interestingly, recent studies highlighted a cru-
cial, dose-dependent role of PTEN in cancer, showing that subtle
reductions in active PTEN levels dictate cancer susceptibility in a
dose-dependent manner (31, 165). However, PTEN loss alone is
sufficient to cause tumorigenesis in some tissues but not in oth-
ers, making the role of PTEN more ambiguous (34). Accordingly,
these data strongly support the hypothesis that PTEN is haploin-
sufficient tumor suppressor and, although PTEN deletion alone
has minimal effects, it frequently contributes to tumorigenesis in
the context of other genetic alterations (31, 166, 167).
PTEN ROLE IN THE REGULATION OF STEM CELL BIOLOGY
Recent data have begun to shed light on the critical role of PTEN in
stem cell maintenance and cancer-initiating cell biology (11, 168).
The effects of PTEN loss in stem cells may be tissue-dependent.
PTEN deletion in neuronal stem cells increases proliferation and
maintains their self-renewing capacity. Similarly, PTEN loss causes
increased proliferation, de-differentiation, and progression toward
prostatic intraepithelial neoplasia in prostate stem cells (30, 59,
168, 169). On the contrary, in both melanocytes and hematopoi-
etic cells, deletion of PTEN leads to normal stem cell exhaustion
(170, 171). PTEN loss has been shown to enhance the number
of tumor initiating cells in a mouse model of leukemia and in
solid tumors, such as breast cancer (172, 173). The role of PTEN
expression and function in the maintenance of lung and colorectal
cancer stem cells (CSC) has not been extensively studied. How-
ever, it is worthy to note that PTEN expression is usually very
low in both lung and colon CSC. Moreover, in colon CSC, PTEN
expression is also strikingly upregulated during differentiation
and by stimuli that inhibit CSC growth and tumorigenic activ-
ity, such as such as BMP4 treatment or thymosin β4 targeting
(11, 174, 175).
PTEN IN MELANOMA
Loss of PTEN plays an important role in the development of 30–
60% of melanomas, however, the mechanisms by which loss of this
gene leads to tumor formation remain uncertain. Recent evidence
has shown that decreased PTEN transcript levels were associated
with PTEN promoter methylation in melanoma (34, 50). Wang
et al. showed that more than 50% of the melanomas from patients
with xeroderma pigmentosum display PTEN mutations, typically
related to ultraviolet radiation exposure, highlighting the link
between DNA-damage and PTEN mutations in this disease (51).
Dankort et al. have demonstrated the ability of PTEN silencing to
cooperate with BRAFV600E mutations in the genesis of metastatic
melanoma (52). Several research groups have recently demon-
strated that MEK blockade may induce compensatory signaling
through PI3K pathway in melanoma, inducing its own resistance
factors and explaining the highly variable clinical responses to
MEK inhibition in different cellular contexts (106, 131, 176–178).
Without a doubt, PTEN status is critical in determining the func-
tional outcome of pharmacologic MEK inhibition in melanoma
and in cellular contexts in which PTEN is genetically unaltered,
MEK blockade induces a cross-talk mechanism that leads to PTEN
protein induction, playing an important, albeit not exclusive, role
in the anti-tumor and anti-angiogenic activities of MEK inhibitors
(106). Consistently, PTEN loss impairs the anti-tumor activity of
MEK inhibitors in preclinical models (106, 179, 180) and correlates
with decreased efficacy of BRAF-targeted treatments in metastatic
melanoma patients (53).
PTEN IN PANCREATIC CANCER
Mouse genetic studies, supported a potential role for PTEN as
a haploinsufficient tumor suppressor. Indeed, homozygous dele-
tion of PTEN in the pancreas leads to metaplasia that may progress
toward frank carcinoma in approximately 20% of cases in trans-
genic mice. Decreased PTEN expression has been demonstrated
in pancreatic tumor cell lines, although deletion or mutations that
cause PTEN loss of activity have not been detected with significant
frequency in human pancreatic ductal adenocarcinoma (PDAC)
(80). In particular, Perren and collaborators have shown that,
although PTEN is not mutated in pancreatic cancers, its subcellular
localization may decrease its function (81). Ying et al. have recently
documented a strong cooperative interaction between KRASG12D
and PTEN loss in promoting metastatic PDAC (82).
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PTEN IN COLORECTAL CANCER
PTEN mutations are relatively prevalent in colorectal cancer and
constitute potential markers of response to EGFR and MAPK
inhibitor-based therapies. In fact, PTEN loss or inactivating muta-
tions are found in a variable proportion (5–30%) of sporadic
colorectal cancers (46, 47, 181). Interestingly, studies performed
in in vivo model systems show that PTEN reactivation in a col-
orectal cancer (CRC) cell line exhibiting PTEN loss reduces its
metastatic capability without affecting primary tumor formation.
Moreover, PTEN reactivation also changed the organotropic hom-
ing from liver and lung metastasis to liver-only metastasis (182).
Importantly, Razis et al. have shown that PTEN levels are predic-
tive of cetuximab efficacy in CRC models with activated EGFR
signaling and wild type KRAS/BRAF status and in the presence of
an intact PI3K/AKT pathway (48).
PTEN IN LUNG CANCER
PTEN mutations occur at a low frequency in NSCLC and in small-
cell lung cancer (SCLC), with the notable exception of squamous
cell carcinoma of the lung, in which PTEN is mutated in 6–9%
of the cases and significantly altered in up to 15% of cases, tak-
ing into account loss of expression as well (72). However, when
detected, PTEN mutations appear to exert an effect on the ther-
apeutic response to EGFR/PI3K pathway inhibitors (73). Since
loss of PTEN protein expression is found in 24–44% of NSCLC
(74), other mechanisms to decrease PTEN expression and function
could be relevant in lung cancer. For example, epigenetic silencing
may partially explain PTEN loss in cases when PTEN mutations
or homozygous deletions are absent (71, 75). Soria et al. have
suggested that 24% of early NSCLC samples lack PTEN expres-
sion, which correlated with PTEN promoter methylation (71).
In addition, Zhang et al. have shown that levels of miR-21 were
upregulated in lung cancer compared with normal lung tissue and
correlate with a reduction in PTEN mRNA levels in advanced
tumor stage (133).
PTEN IN BREAST CANCER
Germline PTEN mutation in Cowden syndrome has a predisposi-
tion to breast cancer, where female CS patients have up to 85% LR
of developing breast cancer (155, 157, 158). In sporadic breast car-
cinomas, the frequency of PTEN loss is 30–40% (36). Epigenetic
aberrations also may cause a decrease in PTEN levels, strongly cor-
relating with tumor stage and grade with complete loss occurring
more frequently in metastatic than in primary tumors (76, 163,
167, 183). In addition, PTEN mutations may overlap with other
mutations including human epidermal growth factor receptor 2
(HER2) and loss of a single PTEN allele has been shown to accel-
erate tumorigenesis in HER2-overexpressing breast tumors (184).
Early studies by Nagata et al. show that, in addition to antagonizing
HER2-driven tumorigenesis, PTEN also sensitizes breast cancer
to trastuzumab treatment (37). In fact, PTEN loss and PTEN-
independent activation of the PI3K pathway were identified as a
major determinant of trastuzumab resistance in preclinical models
and clinical samples as well (37–39, 185).
PTEN IN LEUKEMIA
Although mutations of the PTEN gene appear to be generally
rare in hematological tumors (59), its functional inactivation is
frequently observed in several hematopoietic neoplasms (60–62,
186). Experiments conducted in mice with inducible PTEN dele-
tions have demonstrated that loss of PTEN drives proliferation
of leukemia-initiating cells and promotes leukemogenesis. PI3K
pathway blockade prevents leukemogenesis and restores the nor-
mal self-renewing capacity of hematopoietic stem cells (63, 64).
Cheong et al. have shown that reduction of PTEN phosphoryla-
tion, associated with its inactivity, is observed in approximately
75% of acute myeloid leukemia (AML) patients (65). Another
study has shown that aberrant PTEN transcripts are present in 24%
of AML patients, 80% of cell lines, and 13% of normal controls
analyzed (66). In chronic myeloid leukemia (CML), the BCR–ABL
fusion protein mediates the exclusion of PTEN from the nucleus.
Such effect is reversed upon inactivation of BCR–ABL by imatinib
treatment, which restores PTEN physiological localization local-
ization (67). Recently, it has been shown that PTEN loss accelerates
T-cell acute lymphoblastic leukemia (T-ALL) onset, producing
multiclonal tumors (68, 69). NOTCH1 receptor may inhibit PTEN
expression through the HES-1 transcription factor and this may in
turn lead to AKT activation and resistance to glucocorticoids (70).
Indeed, T-ALL with PTEN loss are resistant to NOTCH1 inhibitors
while they are sensitive to AKT inhibitors (68).
DISCUSSION AND CONCLUSION
PTEN is an extremely powerful and multifaceted tumor suppres-
sor functionally involved in many different “hallmarks” of cancer.
The main mechanism by which PTEN activity restrains cancer
development and progression remains its ability to downmodulate
signaling through the PI3K pathway, thereby indirectly inhibiting
AKT downstream targets, such as GSK3, FOXO, B cell lymphoma 2
(BCL-2) antagonist of cell death (BAD), the E3 ubiquitin–protein
ligase MDM2 and p27, which control survival, cell proliferation,
angiogenesis, and cellular metabolism (187). On the other hand,
the mTORC1 arm of the PI3K/AKT/mTOR pathway is also acti-
vated in response to the loss of PTEN inhibitory activity, resulting
in the phosphorylation of p70 ribosomal protein S6 kinase (S6K;
also known as RPS6K) and inhibition of 4E-binding protein 1
(4EBP1; also known as eIF4EBP1) to activate protein translation
(188, 189) leading to the enhanced translation of specific mRNAs
that are crucial for cell growth and proliferation. Recently, 4EBP1
has indeed emerged as a key negative regulator of cell prolifera-
tion downstream of mTORC1, and its inactivation may directly
promote the growth of sporadic cancers (190, 191).
As discussed above, novel tumor-suppressive functions of
PTEN, independent of its lipid phosphatase activity and abil-
ity to keep the PI3K/AKT/mTOR pathway at bay, have recently
emerged. Among these, functions related to PTEN nuclear local-
ization appear to be particularly interesting (Figure 1B). Indeed,
PTEN cooperates in maintaining genomic integrity, repairing
DNA double-strand breaks, controlling homologous recombina-
tion, and promoting ubiquitin-dependent degradation of onco-
proteins such as polo-like kinase 1 (PLK1) and Aurora kinases
(AURK). This is particularly important, as loss of these PTEN
activities may actually crucially sensitize tumor cells to the cyto-
toxic action of inhibitors of the DNA repair enzyme poly (ADP-
ribose) polymerase (PARP) and have important implications in
tumor cell sensitivity to PLK and AURK inhibitors (24, 192–194).
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Similarly, the phosphatase-independent role played by PTEN in
controlling non-canonical signaling pathways, such as the JNK
pathway (26), the eukaryotic translation initiation factor 2α kinase
2 (eIF2αK2; also known as PKR) – eIF2α phosphorylation cas-
cade (28) or MSP58-mediated cellular transformation (27), and its
ability to dephosphorylate protein substrates, such as FAK (195),
cAMP responsive-element-binding protein (CREB) (196), and the
non-receptor Tyr kinase SRC (29), may have important implica-
tions for the development of rational pharmacological combina-
tions simultaneously targeting the PI3K/AKT and other relevant
pathways.
Along these lines, another interesting indication toward the
possible therapeutic exploitation of PTEN loss in human can-
cer is the observation that PTEN critically lies at the intersec-
tion of two major survival/proliferation pathways, the canonical
PI3K/AKT/mTOR pathway (of which PTEN is an integral part),
and the RAS/MEK/ERK pathway (11). Our group has recently
shown that MEK inhibition restores PTEN expression in tumor
cells with an intact PTEN gene by inhibiting a re-wired MEK–
ERK–c-Jun/miR-25 survival pathway. Under these conditions,
combined MEK/mTOR blockade may exert frank antagonistic
effects in terms of inhibition of VEGF production and tumor cell
growth (106). Conversely, loss of PTEN activity marks a func-
tional state of relative resistance to the growth-inhibitory and
anti-angiogenic activity of MEK inhibitors (53, 106, 179, 180),
raising the interesting hypothesis that combined pharmacologi-
cal inhibition of the MEK/ERK and PI3K/AKT/mTOR may result
in highly synergistic anti-tumor activity selectively in PTEN-null
tumors (11, 106, 197).
Synthetic lethality-based and rational combinatorial strategies
highlighted above are two of the possible approaches to address
the problem that usually happens with loss-of-function “onco-
genic drivers,” restoring the oncosuppressive activity of a missing
PTEN gene/protein by pharmacological means may be difficult.
However, given the importance of non-genomic mechanisms reg-
ulating PTEN expression in those cases where the PTEN gene is
conserved, epigenetic therapy through pharmacological modula-
tion of histone acetylation status or promoter methylation, as well
as inhibition of signaling pathways that are known to regulate
PTEN expression, are particularly attractive, alone or in combina-
tion with inhibitors of other signaling pathways, whose activation
is known to cooperate with PTEN loss in driving the different
aspects of the neoplastic phenotype (198).
Finally, identification of clinical situations in which loss of
PTEN activity is a major driving force, and hence PTEN-based
therapeutics may be exquisitely effective, is cumbersome. The
exceptionally complex regulation of PTEN activity calls for a more
comprehensive assessment of PTEN status in human tumors.
This should encompass sequencing the entire PTEN gene, tran-
scriptional, and protein expression analysis, as well as assess-
ment of post-translational modifications and subcellular local-
ization. An alternative possibility could be to develop functional
(genomic, transcriptional, or proteomic) “signatures” of loss of
PTEN function. Although, such approach would require extensive
validation to identify reliable surrogate(s) for PTEN loss, prelim-
inary evidence suggests that “signatures” of PTEN loss may be
developed and may identify patients/tissues with loss of PTEN
function more efficiently than immunohistochemistry for the
PTEN protein (26, 76).
Loss of the many PTEN activities remains a crucial event in the
development and progression of a vast and ever increasing pro-
portion of human cancers. Even though little progress has been
made so far in developing agents to therapeutically enhance the
tumor-suppressive functions of PTEN, there is little doubt that
with the current rapid expansion of knowledge on PTEN func-
tions and regulation, its exploitation for therapeutic purposes will
soon become a reality for many cancer patients.
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